Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 03 2023
Historique:
pmc-release: 25 01 2024
pubmed: 26 1 2023
medline: 4 3 2023
entrez: 25 1 2023
Statut: ppublish

Résumé

No clinically applicable diagnostic test exists for severe mental disorders. Lipids harbor potential as disease markers. To define a reproducible profile of lipid alterations in the blood plasma of patients with schizophrenia (SCZ) independent of demographic and environmental variables and to investigate its specificity in association with other psychiatric disorders, ie, major depressive disorder (MDD) and bipolar disorder (BPD). This was a multicohort case-control diagnostic analysis involving plasma samples from psychiatric patients and control individuals collected between July 17, 2009, and May 18, 2018. Study participants were recruited as consecutive and volunteer samples at multiple inpatient and outpatient mental health hospitals in Western Europe (Germany and Austria [DE-AT]), China (CN), and Russia (RU). Individuals with DSM-IV or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses of SCZ, MDD, BPD, or a first psychotic episode, as well as age- and sex-matched healthy controls without a mental health-related diagnosis were included in the study. Samples and data were analyzed from January 2018 to September 2020. Plasma lipidome composition was assessed using liquid chromatography coupled with untargeted mass spectrometry. Blood lipid levels were assessed in 980 individuals (mean [SD] age, 36 [13] years; 510 male individuals [52%]) diagnosed with SCZ, BPD, MDD, or those with a first psychotic episode and in 572 controls (mean [SD] age, 34 [13] years; 323 male individuals [56%]). A total of 77 lipids were found to be significantly altered between those with SCZ (n = 436) and controls (n = 478) in all 3 sample cohorts. Alterations were consistent between cohorts (CN and RU: [Pearson correlation] r = 0.75; DE-AT and CN: r = 0.78; DE-AT and RU: r = 0.82; P < 10-38). A lipid-based predictive model separated patients with SCZ from controls with high diagnostic ability (area under the receiver operating characteristic curve = 0.86-0.95). Lipidome alterations in BPD and MDD, assessed in 184 and 256 individuals, respectively, were found to be similar to those of SCZ (BPD: r = 0.89; MDD: r = 0.92; P < 10-79). Assessment of detected alterations in individuals with a first psychotic episode, as well as patients with SCZ not receiving medication, demonstrated only limited association with medication restricted to particular lipids. In this study, SCZ was accompanied by a reproducible profile of plasma lipidome alterations, not associated with symptom severity, medication, and demographic and environmental variables, and largely shared with BPD and MDD. This lipid alteration signature may represent a trait marker of severe psychiatric disorders, indicating its potential to be transformed into a clinically applicable testing procedure.

Identifiants

pubmed: 36696101
pii: 2800311
doi: 10.1001/jamapsychiatry.2022.4350
pmc: PMC9878436
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-259

Auteurs

Anna Tkachev (A)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.
Institute for Information Transmission Problems, Russian Academy of Sciences, Moscow, Russia.

Elena Stekolshchikova (E)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Anna Vanyushkina (A)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Hanping Zhang (H)

NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Anna Morozova (A)

Department Basic and Applied Neurobiology, V. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Moscow, Russia.
Moscow Psychiatric Hospital No. 1, named after N.A. Alekseev, Moscow, Russia.

Svetlana Zozulya (S)

Mental Health Research Center, Moscow, Russia.

Ilia Kurochkin (I)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Nickolay Anikanov (N)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Alina Egorova (A)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Ekaterina Yushina (E)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.
FSBSI N.P. Bochkov Research Center of Medical Genetics, Moscow, Russia.

Thomas Vogl (T)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Fanny Senner (F)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Sabrina K Schaupp (SK)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Daniela Reich-Erkelenz (D)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Sergi Papiol (S)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Mojtaba Oraki Kohshour (MO)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Farahnaz Klöhn-Saghatolislam (F)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Janos L Kalman (JL)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Urs Heilbronner (U)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Maria Heilbronner (M)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Katrin Gade (K)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Ashley L Comes (AL)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Monika Budde (M)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Heike Anderson-Schmidt (H)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Kristina Adorjan (K)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Jens Wiltfang (J)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
German Center for Neurodegenerative Diseases, Göttingen, Germany.
Neurosciences and Signaling Group, Institute of Medicine, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Eva Z Reininghaus (EZ)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Neurobiology and Anthropometrics in Bipolar Affective Disorder, Medical University of Graz, Graz, Austria.

Georg Juckel (G)

Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, Germany.

Udo Dannlowski (U)

Institute for Translational Psychiatry, University of Münster, Münster, Germany.

Andreas Fallgatter (A)

Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health, University Tübingen, Tübingen, Germany.

Carsten Spitzer (C)

Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Rostock, Rostock, Germany.

Max Schmauß (M)

Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Augsburg, Augsburg, Germany.

Martin von Hagen (M)

Clinic for Psychiatry and Psychotherapy, Clinical Center Werra-Meißner, Eschwege, Germany.

Yana Zorkina (Y)

Department Basic and Applied Neurobiology, V. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Moscow, Russia.
Moscow Psychiatric Hospital No. 1, named after N.A. Alekseev, Moscow, Russia.

Alexander Reznik (A)

Moscow Psychiatric Hospital No. 1, named after N.A. Alekseev, Moscow, Russia.
Moscow State University of Food Production, Moscow, Russia.

Aleksandra Barkhatova (A)

Mental Health Research Center, Moscow, Russia.

Roman Lisov (R)

Institute for Information Transmission Problems, Russian Academy of Sciences, Moscow, Russia.
Moscow Institute of Physics and Technology, Dolgoprudny, Russia.

Nikita Mokrov (N)

Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
Center for Artificial Intelligence Technologies, Skolkovo Institute of Science and Technology, Moscow, Russia.

Maxim Panov (M)

Technology Innovation Institute, Abu Dhabi, United Arab Emirates.

Dmitri Zubkov (D)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Daria Petrova (D)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Chanjuan Zhou (C)

NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.

Yiyun Liu (Y)

NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Juncai Pu (J)

NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

Georgiy Kostyuk (G)

Moscow Psychiatric Hospital No. 1, named after N.A. Alekseev, Moscow, Russia.

Tatiana Klyushnik (T)

Mental Health Research Center, Moscow, Russia.

Thomas G Schulze (TG)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.

Peng Xie (P)

NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Key Laboratory of Neurobiology, Chongqing, China.

Eva C Schulte (EC)

Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital Bonn, medical Faculty University of Bonn, Bonn, Germany.

Philipp Khaitovich (P)

Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH